{
  "id": 18054899,
  "title": "Celltrion Unveils First Quadruple-Action Obesity Drug Candidate, Outperforming Retatrutide in Animal Study",
  "url": "https://urgent.news/2026/11/04/celltrion-unveils-first-quadruple-action-obesity-drug-candidate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-04T02:28:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=280397"
  },
  "original_language": "en",
  "account": "Celltrion has unveiled its first quadruple-action obesity drug candidate, CT-G32/SCO-940, which outperformed the triple agonist retatrutide in preclinical animal studies. The company showcased the potential of this novel treatment at TIDES Europe 2026, highlighting its ability to simultaneously target four hormonal pathways: GLP-1, GIP, glucagon, and amylin. In overweight animal models, CT-G32/SCO-940 resulted in greater weight loss compared to retatrutide while preserving more lean mass, including muscle and bone. Additionally, the drug candidate demonstrated the capacity to lower excessively high blood insulin levels, suggesting possible applications in metabolic conditions beyond obesity, such as hyperinsulinemia. Following preclinical success, Celltrion plans to submit an Investigational New Drug (IND) application to the FDA by February 2027, with the goal of initiating patient dosing in the second quarter of the same year.",
  "summary": "Celltrion has unveiled preclinical data for CT-G32/SCO-940, a next-generation obesity drug candidate designed to target four hormonal pathways: GLP-1, GIP, glucagon, and amylin. According to Korea IT Times, the research was conducted jointly with Japan-based SCOHIA PHARMA and presented at TIDES Europe in Amsterdam. Celltrion stated that this is the world's first obesity drug candidate publicly disclosed to target all four pathways simultaneously.\n\nIn animal studies using diet-induced obese rat models, CT-G32/SCO-940 demonstrated greater weight-loss effects than retatrutide when administered at the same dose, according to Korea IT Times. The candidate also showed potential advantages in body composition, with a relatively lower proportion of lean body mass loss, such as muscle and skeletal components, compared to the comparator drug.\n\nBusinessKorea reports that Celltrion is accelerating the development of the quadruple agonist to address limitations in existing treatments. The company aims to advance the candidate into global clinical trials in 2027, according to Korea IT Times.",
  "key_points": [
    "Celltrion unveils first quadruple-action obesity drug candidate, CT-G32/SCO-940",
    "Outperforms retatrutide in preclinical animal studies",
    "Targets GLP-1, GIP, glucagon, and amylin pathways"
  ],
  "editors_take": "Targeting four hormonal pathways instead of three positions Celltrion to challenge existing obesity treatments by offering superior weight loss and better preservation of muscle and bone mass.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Korea IT Times",
        "title": "Celltrion Unveils World’s First Quadruple-Agonist Obesity Drug Candidate, CT-G32/SCO-940",
        "url": "https://urgent.news/2026/11/04/celltrion-unveils-worlds-first-quadruple-agonist-obesity-drug",
        "published": "2026-11-04T01:10:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}